Fc[gamma]R and EGFR Polymorphisms as Predictive Markers of Cetuximab Efficacy in Metastatic Colorectal Cancer

Cetuximab shows activity in KRAS (Kirsten rat sarcoma viral oncogene homolog) wildtype metastatic colorectal cancer (mCRC). Recent studies have demonstrated that cetuximab induces antibodydependent cell-mediated cytotoxicity (ADCC) in mCRC. The authors investigated the associations of FcγR (fragment...

Full description

Saved in:
Bibliographic Details
Published in:Molecular diagnosis & therapy 2014-10, Vol.18 (5), p.541
Main Authors: Inoue, Yuka, Hazama, Shoichi, Iwamoto, Shigeyoshi, Miyake, Yasuhiro, Matsuda, Chu, Tsunedomi, Ryouichi, Okayama, Naoko, Hinoda, Yuji, Yamasaki, Takahiro, Suehiro, Yutaka, Yoshino, Shigefumi, Sakamoto, Junichi, Mishima, Hideyuki, Oka, Masaaki
Format: Article
Language:English
Subjects:
Cancer therapies
Colorectal cancer
Cytotoxicity
Drug therapy
Genes
Ligands
Metastasis
Mortality
Polymorphism
Response rates
Studies
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 5
container_start_page 541
container_title Molecular diagnosis & therapy
container_volume 18
creator Inoue, Yuka
Hazama, Shoichi
Iwamoto, Shigeyoshi
Miyake, Yasuhiro
Matsuda, Chu
Tsunedomi, Ryouichi
Okayama, Naoko
Hinoda, Yuji
Yamasaki, Takahiro
Suehiro, Yutaka
Yoshino, Shigefumi
Sakamoto, Junichi
Mishima, Hideyuki
Oka, Masaaki
description Cetuximab shows activity in KRAS (Kirsten rat sarcoma viral oncogene homolog) wildtype metastatic colorectal cancer (mCRC). Recent studies have demonstrated that cetuximab induces antibodydependent cell-mediated cytotoxicity (ADCC) in mCRC. The authors investigated the associations of FcγR (fragment C γ receptor) and EGFR (epidermal growth factor receptor) polymorphisms with the outcome of mCRC patients treated with cetuximab and FOLFIRI (folic acid/5-fluorouracil/irinotecan) as second-line therapy in the FLIER (Cetuximab Plus Folinic Acid/5-Fluorouracil/Irinotecan in KRAS Wild-Type Metastatic Colorectal Cancer as a Second-Line Treatment) study. A total of 57 patients were evaluated in this study. The association of each polymorphism with the response rate, progression-free survival, and overall survival was analyzed. The data suggest that FccR and EGFR CA repeat polymorphisms may be associated with the outcome of mCRC patients treated with cetuximab and FOLFIRI, although further investigations will be needed to confirm the association of FccR and EGFR polymorphisms with the efficacy of cetuximab.
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1624930450</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3495126421</sourcerecordid><originalsourceid>FETCH-proquest_journals_16249304503</originalsourceid><addsrcrecordid>eNqNjssKwjAQRYMo-PyHAdeFtGql69LqRhBxJ1LGONVo02gmFf17RfwAV_fAOYvbEr0wnCdBJKVsf3kehDKOuqLPfJFyOouTqCdMrnYnNAb3G8D6CNki38DaVi9j3e2s2TAgw9rRUSuvHwQrdFdyDLaElHzz1AYPkJWlVqheoGtYkUf26LWC1FbWkfJYQYq1IjcUnRIrptFvB2KcZ9t0GdycvTfEvrjYxtUfVYRxNE0mn5ty8l_1BoCESiM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1624930450</pqid></control><display><type>article</type><title>Fc[gamma]R and EGFR Polymorphisms as Predictive Markers of Cetuximab Efficacy in Metastatic Colorectal Cancer</title><source>Springer Nature</source><creator>Inoue, Yuka ; Hazama, Shoichi ; Iwamoto, Shigeyoshi ; Miyake, Yasuhiro ; Matsuda, Chu ; Tsunedomi, Ryouichi ; Okayama, Naoko ; Hinoda, Yuji ; Yamasaki, Takahiro ; Suehiro, Yutaka ; Yoshino, Shigefumi ; Sakamoto, Junichi ; Mishima, Hideyuki ; Oka, Masaaki</creator><creatorcontrib>Inoue, Yuka ; Hazama, Shoichi ; Iwamoto, Shigeyoshi ; Miyake, Yasuhiro ; Matsuda, Chu ; Tsunedomi, Ryouichi ; Okayama, Naoko ; Hinoda, Yuji ; Yamasaki, Takahiro ; Suehiro, Yutaka ; Yoshino, Shigefumi ; Sakamoto, Junichi ; Mishima, Hideyuki ; Oka, Masaaki</creatorcontrib><description>Cetuximab shows activity in KRAS (Kirsten rat sarcoma viral oncogene homolog) wildtype metastatic colorectal cancer (mCRC). Recent studies have demonstrated that cetuximab induces antibodydependent cell-mediated cytotoxicity (ADCC) in mCRC. The authors investigated the associations of FcγR (fragment C γ receptor) and EGFR (epidermal growth factor receptor) polymorphisms with the outcome of mCRC patients treated with cetuximab and FOLFIRI (folic acid/5-fluorouracil/irinotecan) as second-line therapy in the FLIER (Cetuximab Plus Folinic Acid/5-Fluorouracil/Irinotecan in KRAS Wild-Type Metastatic Colorectal Cancer as a Second-Line Treatment) study. A total of 57 patients were evaluated in this study. The association of each polymorphism with the response rate, progression-free survival, and overall survival was analyzed. The data suggest that FccR and EGFR CA repeat polymorphisms may be associated with the outcome of mCRC patients treated with cetuximab and FOLFIRI, although further investigations will be needed to confirm the association of FccR and EGFR polymorphisms with the efficacy of cetuximab.</description><identifier>ISSN: 1177-1062</identifier><identifier>EISSN: 1179-2000</identifier><language>eng</language><publisher>Auckland: Springer Nature B.V</publisher><subject>Cancer therapies ; Colorectal cancer ; Cytotoxicity ; Drug therapy ; Genes ; Ligands ; Metastasis ; Mortality ; Polymorphism ; Response rates ; Studies ; Tumors</subject><ispartof>Molecular diagnosis &amp; therapy, 2014-10, Vol.18 (5), p.541</ispartof><rights>Copyright Wolters Kluwer Health Adis International Oct 2014</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Inoue, Yuka</creatorcontrib><creatorcontrib>Hazama, Shoichi</creatorcontrib><creatorcontrib>Iwamoto, Shigeyoshi</creatorcontrib><creatorcontrib>Miyake, Yasuhiro</creatorcontrib><creatorcontrib>Matsuda, Chu</creatorcontrib><creatorcontrib>Tsunedomi, Ryouichi</creatorcontrib><creatorcontrib>Okayama, Naoko</creatorcontrib><creatorcontrib>Hinoda, Yuji</creatorcontrib><creatorcontrib>Yamasaki, Takahiro</creatorcontrib><creatorcontrib>Suehiro, Yutaka</creatorcontrib><creatorcontrib>Yoshino, Shigefumi</creatorcontrib><creatorcontrib>Sakamoto, Junichi</creatorcontrib><creatorcontrib>Mishima, Hideyuki</creatorcontrib><creatorcontrib>Oka, Masaaki</creatorcontrib><title>Fc[gamma]R and EGFR Polymorphisms as Predictive Markers of Cetuximab Efficacy in Metastatic Colorectal Cancer</title><title>Molecular diagnosis &amp; therapy</title><description>Cetuximab shows activity in KRAS (Kirsten rat sarcoma viral oncogene homolog) wildtype metastatic colorectal cancer (mCRC). Recent studies have demonstrated that cetuximab induces antibodydependent cell-mediated cytotoxicity (ADCC) in mCRC. The authors investigated the associations of FcγR (fragment C γ receptor) and EGFR (epidermal growth factor receptor) polymorphisms with the outcome of mCRC patients treated with cetuximab and FOLFIRI (folic acid/5-fluorouracil/irinotecan) as second-line therapy in the FLIER (Cetuximab Plus Folinic Acid/5-Fluorouracil/Irinotecan in KRAS Wild-Type Metastatic Colorectal Cancer as a Second-Line Treatment) study. A total of 57 patients were evaluated in this study. The association of each polymorphism with the response rate, progression-free survival, and overall survival was analyzed. The data suggest that FccR and EGFR CA repeat polymorphisms may be associated with the outcome of mCRC patients treated with cetuximab and FOLFIRI, although further investigations will be needed to confirm the association of FccR and EGFR polymorphisms with the efficacy of cetuximab.</description><subject>Cancer therapies</subject><subject>Colorectal cancer</subject><subject>Cytotoxicity</subject><subject>Drug therapy</subject><subject>Genes</subject><subject>Ligands</subject><subject>Metastasis</subject><subject>Mortality</subject><subject>Polymorphism</subject><subject>Response rates</subject><subject>Studies</subject><subject>Tumors</subject><issn>1177-1062</issn><issn>1179-2000</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNqNjssKwjAQRYMo-PyHAdeFtGql69LqRhBxJ1LGONVo02gmFf17RfwAV_fAOYvbEr0wnCdBJKVsf3kehDKOuqLPfJFyOouTqCdMrnYnNAb3G8D6CNki38DaVi9j3e2s2TAgw9rRUSuvHwQrdFdyDLaElHzz1AYPkJWlVqheoGtYkUf26LWC1FbWkfJYQYq1IjcUnRIrptFvB2KcZ9t0GdycvTfEvrjYxtUfVYRxNE0mn5ty8l_1BoCESiM</recordid><startdate>20141001</startdate><enddate>20141001</enddate><creator>Inoue, Yuka</creator><creator>Hazama, Shoichi</creator><creator>Iwamoto, Shigeyoshi</creator><creator>Miyake, Yasuhiro</creator><creator>Matsuda, Chu</creator><creator>Tsunedomi, Ryouichi</creator><creator>Okayama, Naoko</creator><creator>Hinoda, Yuji</creator><creator>Yamasaki, Takahiro</creator><creator>Suehiro, Yutaka</creator><creator>Yoshino, Shigefumi</creator><creator>Sakamoto, Junichi</creator><creator>Mishima, Hideyuki</creator><creator>Oka, Masaaki</creator><general>Springer Nature B.V</general><scope>3V.</scope><scope>4T-</scope><scope>7QO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20141001</creationdate><title>Fc[gamma]R and EGFR Polymorphisms as Predictive Markers of Cetuximab Efficacy in Metastatic Colorectal Cancer</title><author>Inoue, Yuka ; Hazama, Shoichi ; Iwamoto, Shigeyoshi ; Miyake, Yasuhiro ; Matsuda, Chu ; Tsunedomi, Ryouichi ; Okayama, Naoko ; Hinoda, Yuji ; Yamasaki, Takahiro ; Suehiro, Yutaka ; Yoshino, Shigefumi ; Sakamoto, Junichi ; Mishima, Hideyuki ; Oka, Masaaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_16249304503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Cancer therapies</topic><topic>Colorectal cancer</topic><topic>Cytotoxicity</topic><topic>Drug therapy</topic><topic>Genes</topic><topic>Ligands</topic><topic>Metastasis</topic><topic>Mortality</topic><topic>Polymorphism</topic><topic>Response rates</topic><topic>Studies</topic><topic>Tumors</topic><toplevel>online_resources</toplevel><creatorcontrib>Inoue, Yuka</creatorcontrib><creatorcontrib>Hazama, Shoichi</creatorcontrib><creatorcontrib>Iwamoto, Shigeyoshi</creatorcontrib><creatorcontrib>Miyake, Yasuhiro</creatorcontrib><creatorcontrib>Matsuda, Chu</creatorcontrib><creatorcontrib>Tsunedomi, Ryouichi</creatorcontrib><creatorcontrib>Okayama, Naoko</creatorcontrib><creatorcontrib>Hinoda, Yuji</creatorcontrib><creatorcontrib>Yamasaki, Takahiro</creatorcontrib><creatorcontrib>Suehiro, Yutaka</creatorcontrib><creatorcontrib>Yoshino, Shigefumi</creatorcontrib><creatorcontrib>Sakamoto, Junichi</creatorcontrib><creatorcontrib>Mishima, Hideyuki</creatorcontrib><creatorcontrib>Oka, Masaaki</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Biotechnology Research Abstracts</collection><collection>Health &amp; Medical Complete (ProQuest Database)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Molecular diagnosis &amp; therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Inoue, Yuka</au><au>Hazama, Shoichi</au><au>Iwamoto, Shigeyoshi</au><au>Miyake, Yasuhiro</au><au>Matsuda, Chu</au><au>Tsunedomi, Ryouichi</au><au>Okayama, Naoko</au><au>Hinoda, Yuji</au><au>Yamasaki, Takahiro</au><au>Suehiro, Yutaka</au><au>Yoshino, Shigefumi</au><au>Sakamoto, Junichi</au><au>Mishima, Hideyuki</au><au>Oka, Masaaki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fc[gamma]R and EGFR Polymorphisms as Predictive Markers of Cetuximab Efficacy in Metastatic Colorectal Cancer</atitle><jtitle>Molecular diagnosis &amp; therapy</jtitle><date>2014-10-01</date><risdate>2014</risdate><volume>18</volume><issue>5</issue><spage>541</spage><pages>541-</pages><issn>1177-1062</issn><eissn>1179-2000</eissn><abstract>Cetuximab shows activity in KRAS (Kirsten rat sarcoma viral oncogene homolog) wildtype metastatic colorectal cancer (mCRC). Recent studies have demonstrated that cetuximab induces antibodydependent cell-mediated cytotoxicity (ADCC) in mCRC. The authors investigated the associations of FcγR (fragment C γ receptor) and EGFR (epidermal growth factor receptor) polymorphisms with the outcome of mCRC patients treated with cetuximab and FOLFIRI (folic acid/5-fluorouracil/irinotecan) as second-line therapy in the FLIER (Cetuximab Plus Folinic Acid/5-Fluorouracil/Irinotecan in KRAS Wild-Type Metastatic Colorectal Cancer as a Second-Line Treatment) study. A total of 57 patients were evaluated in this study. The association of each polymorphism with the response rate, progression-free survival, and overall survival was analyzed. The data suggest that FccR and EGFR CA repeat polymorphisms may be associated with the outcome of mCRC patients treated with cetuximab and FOLFIRI, although further investigations will be needed to confirm the association of FccR and EGFR polymorphisms with the efficacy of cetuximab.</abstract><cop>Auckland</cop><pub>Springer Nature B.V</pub></addata></record>
fulltext fulltext
identifier ISSN: 1177-1062
ispartof Molecular diagnosis & therapy, 2014-10, Vol.18 (5), p.541
issn 1177-1062
1179-2000
language eng
recordid cdi_proquest_journals_1624930450
source Springer Nature
subjects Cancer therapies
Colorectal cancer
Cytotoxicity
Drug therapy
Genes
Ligands
Metastasis
Mortality
Polymorphism
Response rates
Studies
Tumors
title Fc[gamma]R and EGFR Polymorphisms as Predictive Markers of Cetuximab Efficacy in Metastatic Colorectal Cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T21%3A22%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fc%5Bgamma%5DR%20and%20EGFR%20Polymorphisms%20as%20Predictive%20Markers%20of%20Cetuximab%20Efficacy%20in%20Metastatic%20Colorectal%20Cancer&rft.jtitle=Molecular%20diagnosis%20&%20therapy&rft.au=Inoue,%20Yuka&rft.date=2014-10-01&rft.volume=18&rft.issue=5&rft.spage=541&rft.pages=541-&rft.issn=1177-1062&rft.eissn=1179-2000&rft_id=info:doi/&rft_dat=%3Cproquest%3E3495126421%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_journals_16249304503%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1624930450&rft_id=info:pmid/&rfr_iscdi=true